# Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

> **NCT01097096** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 177 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** CAD106
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Alum
- **BIOLOGICAL:** MF59

## Key facts

- **NCT ID:** NCT01097096
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2021-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01097096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01097096, "Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01097096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*